Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2019

01-05-2019 | Multiple Myeloma | Letter to the Editor

Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support

Authors: Claudio Cerchione, Amalia De Renzo, Davide Nappi, Maria Di Perna, Roberta Della Pepa, Novella Pugliese, Lucio Catalano, Fabrizio Pane, Marco Picardi

Published in: Supportive Care in Cancer | Issue 5/2019

Login to get access

Excerpt

Dear editor, …
Literature
1.
Imataki O, Uchida S, Yokokura S, Uemura M, Kadowaki N (2018) Bendamustine and G-CSF support. Support Care Cancer
2.
Cerchione C, De Renzo A, Di Perna M et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer 25(3):839–845CrossRefPubMed
3.
Balducci L, Repetto L (2004) Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100(1):6–11CrossRef
4.
Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25(10):3123–3132CrossRefPubMed
5.
Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. Oncologist 23(4):454–460CrossRefPubMedPubMedCentral
6.
Cerchione C, Catalano L, Pareto AE et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301–302CrossRef
7.
Cerchione C, Catalano L, Peluso I, Nappi D, di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F (2016) Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. Support Care Cancer 24(12):4835–4837CrossRefPubMedPubMedCentral
8.
Cerchione C, Nappi D, Di Perna M et al (2017) A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide. Clin Case Rep 5(4):505–507CrossRefPubMedPubMedCentral
9.
Cerchione C, Nappi D, Di Perna M et al (2016) Retreatment with bendamustine-bortezomib-dexamethasone in a patient with relapsed/refractory multiple myeloma. Case Rep Hematol 2016:6745286PubMedPubMedCentral
Metadata
Title
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support
Authors
Claudio Cerchione
Amalia De Renzo
Davide Nappi
Maria Di Perna
Roberta Della Pepa
Novella Pugliese
Lucio Catalano
Fabrizio Pane
Marco Picardi
Publication date
01-05-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-4651-5

Other articles of this Issue 5/2019

Supportive Care in Cancer 5/2019 Go to the issue

Original Article

The influence of partner involvement in the decision-making process on body image and decision regret among women receiving breast reconstruction

Original Article

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit

Original Article

Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy

Original Article

Oral and dental alterations and growth disruption following chemotherapy in long-term survivors of childhood malignancies

Original Article

Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer

Original Article

Reimagine: a randomized controlled trial of an online, symptom self-management curriculum among breast cancer survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits